Marco Witteveen

I help startups in medical products, services, and technology go from early-stage spark to global scale. As a senior executive and growth catalyst, I bring strategic clarity, commercialisation expertise, and the ability to rapidly adapt to market shifts. With a track record in business planning, product and market strategy, and global market entry, I’ve partnered […]

Jay Roberts

Jay Roberts has been a senior strategic executive in the healthcare industry for over 30 years. He is a partner with Ventac Partners, a global catalyst in life sciences creating breakthrough companies bringing remarkable scientific innovation to patients worldwide. He also serves as a Venture Partner for DigiLife Fund II, leading fundraising, due diligence and […]

Siham Ceballos

I am a senior biotech and pharma strategist with over 20 years of experience across medical affairs, clinical development, external innovation, portfolio strategy, and venture-facing due diligence. My background spans oncology, hematology, rare diseases, RNA therapeutics, CNS, dermatology, regenerative medicine, and longevity biology. I have held leadership roles in global and regional organizations, including Celgene, […]

Juhani Lahdenperä

I am the Founder of Biotech Start-Up Management Ltd., specializing in AI-enabled life science due diligence, business development, funding strategy, and partnerships. My work focuses on helping investors, biotech companies, and digital health ventures evaluate opportunities faster and more systematically by combining sector expertise with AI-supported document analysis. I support projects involving biotech, medtech, digital […]

Raymond Stevens

Ray Stevens is a biotech executive, company builder, and drug development operator with experience across CMC, IND strategy, translational development, clinical planning, commercialization, financing, and fundraising strategy. He helps early and mid stage life sciences companies convert complex science into credible, executable development plans. Ray works with teams to clarify the next highest value experiment, […]

Peter Crosby

Peter Crosby is a seasoned medical device industry executive with extensive international leadership experience, having served as Chief Executive Officer for six medical device companies across four countries. He currently runsBiomedical Business Resources LLC, providing strategic advisory services to the biomedical sector. He has served as an expert witness on dozens of cases, with emphasis […]

Wayne Jensen

I’ve spent 30 years in medtech and biotech—from the bench to the production floor to the C-suite—bringing more than 25 products to market across FDA 510(k), CE/MDR, and TGA pathways. I’ve seen exceptional science fail, not because the innovation wasn’t strong, but because the operational, regulatory, and governance foundations weren’t in place to support commercialization. […]

Dmitry Zamoryakhin, MD MBA

I help bring new cancer and rare disease treatments to patients, guiding projects from early research all the way through clinical trials. Over the years, I’ve worked with a range of therapies – from small molecules and drug‐device combos to CAR-T/TCR-T cells, viral vector-based gene therapies, oncolytic viruses, antibodies, ADCs, and intratumoral delivery. I’ve led […]

Jeff Spitzner

I am a 12x founder of life sciences technology startups, having raised over $30 million across my portfolio, with both successful exits and ongoing ventures. My companies have spanned biotechnology, software, medical devices, cosmeceuticals, gene therapy, and a venture studio investment platform. My expertise lies in technology commercialization — bringing innovative products from concept to […]

Yoel Bakas, MBA

I am Founder and Managing Director of Medsolve Dynamics, an oncology advisory firm focused on operational strategy, capital alignment, and reimbursement-driven purchasing for radiation oncology programs. I bring 20+ years of executive leadership across oncology technology, including senior roles at Varian, Mevion, ViewRay, and GE HealthCare, working at the intersection of oncology strategy and AI-enabled […]